S-adenosyl-L-methionine treatment for alcoholic liver disease

A double-blinded, randomized, placebo-controlled trial

Valentina Medici, Maria C. Virata, Janet M. Peerson, Sally P. Stabler, Samuel W. French, Jesse F. Gregory, Anthony Albanese, Christopher Bowlus, Sridevi Devaraj, Edward A Panacek, John R Richards, Charles H. Halsted

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: S-adenosyl-L-methionine (SAM) is the methyl donor for all methylation reactions and regulates the synthesis of glutathione, the main cellular antioxidant. Previous experimental studies suggested that SAM may benefit patients with established alcoholic liver diseases (ALDs). The aim of this study was to determine the efficacy of SAM in treatment for ALD in a 24-week trial. The primary endpoints were changes in serum aminotransferase levels and liver histopathology scores, and the secondary endpoints were changes in serum levels of methionine metabolites. Methods: We randomized 37 patients with ALD to receive 1.2g of SAM by mouth or placebo daily. Subjects were required to remain abstinent from alcohol drinking. A baseline liver biopsy was performed in 24 subjects, and a posttreatment liver biopsy was performed in 14 subjects. Results: Fasting serum SAM levels were increased over timed intervals in the SAM treatment group. The entire cohort showed an overall improvement of AST, ALT, and bilirubin levels after 24weeks of treatment, but there were no differences between the treatment groups in any clinical or biochemical parameters nor any intra- or intergroup differences or changes in liver histopathology scores for steatosis, inflammation, fibrosis, and Mallory-Denk hyaline bodies. Conclusions: Whereas abstinence improved liver function, 24weeks of therapy with SAM was no more effective than placebo in the treatment for ALD.

Original languageEnglish (US)
Pages (from-to)1960-1965
Number of pages6
JournalAlcoholism: Clinical and Experimental Research
Volume35
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

S-Adenosylmethionine
Alcoholic Liver Diseases
Liver
Randomized Controlled Trials
Placebos
Therapeutics
Biopsy
Serum
Hyalin
Transaminases
Bilirubin
Alcohol Drinking
Methionine
Methylation
Glutathione
Mouth
Fasting
Metabolites
Fibrosis
Antioxidants

Keywords

  • Alcoholic liver disease
  • S-adenosyl-L-methionine
  • S-adenosylmethionine

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Toxicology

Cite this

S-adenosyl-L-methionine treatment for alcoholic liver disease : A double-blinded, randomized, placebo-controlled trial. / Medici, Valentina; Virata, Maria C.; Peerson, Janet M.; Stabler, Sally P.; French, Samuel W.; Gregory, Jesse F.; Albanese, Anthony; Bowlus, Christopher; Devaraj, Sridevi; Panacek, Edward A; Richards, John R; Halsted, Charles H.

In: Alcoholism: Clinical and Experimental Research, Vol. 35, No. 11, 11.2011, p. 1960-1965.

Research output: Contribution to journalArticle

Medici, Valentina ; Virata, Maria C. ; Peerson, Janet M. ; Stabler, Sally P. ; French, Samuel W. ; Gregory, Jesse F. ; Albanese, Anthony ; Bowlus, Christopher ; Devaraj, Sridevi ; Panacek, Edward A ; Richards, John R ; Halsted, Charles H. / S-adenosyl-L-methionine treatment for alcoholic liver disease : A double-blinded, randomized, placebo-controlled trial. In: Alcoholism: Clinical and Experimental Research. 2011 ; Vol. 35, No. 11. pp. 1960-1965.
@article{40ae251f91e44255bb109a563050e037,
title = "S-adenosyl-L-methionine treatment for alcoholic liver disease: A double-blinded, randomized, placebo-controlled trial",
abstract = "Background: S-adenosyl-L-methionine (SAM) is the methyl donor for all methylation reactions and regulates the synthesis of glutathione, the main cellular antioxidant. Previous experimental studies suggested that SAM may benefit patients with established alcoholic liver diseases (ALDs). The aim of this study was to determine the efficacy of SAM in treatment for ALD in a 24-week trial. The primary endpoints were changes in serum aminotransferase levels and liver histopathology scores, and the secondary endpoints were changes in serum levels of methionine metabolites. Methods: We randomized 37 patients with ALD to receive 1.2g of SAM by mouth or placebo daily. Subjects were required to remain abstinent from alcohol drinking. A baseline liver biopsy was performed in 24 subjects, and a posttreatment liver biopsy was performed in 14 subjects. Results: Fasting serum SAM levels were increased over timed intervals in the SAM treatment group. The entire cohort showed an overall improvement of AST, ALT, and bilirubin levels after 24weeks of treatment, but there were no differences between the treatment groups in any clinical or biochemical parameters nor any intra- or intergroup differences or changes in liver histopathology scores for steatosis, inflammation, fibrosis, and Mallory-Denk hyaline bodies. Conclusions: Whereas abstinence improved liver function, 24weeks of therapy with SAM was no more effective than placebo in the treatment for ALD.",
keywords = "Alcoholic liver disease, S-adenosyl-L-methionine, S-adenosylmethionine",
author = "Valentina Medici and Virata, {Maria C.} and Peerson, {Janet M.} and Stabler, {Sally P.} and French, {Samuel W.} and Gregory, {Jesse F.} and Anthony Albanese and Christopher Bowlus and Sridevi Devaraj and Panacek, {Edward A} and Richards, {John R} and Halsted, {Charles H.}",
year = "2011",
month = "11",
doi = "10.1111/j.1530-0277.2011.01547.x",
language = "English (US)",
volume = "35",
pages = "1960--1965",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - S-adenosyl-L-methionine treatment for alcoholic liver disease

T2 - A double-blinded, randomized, placebo-controlled trial

AU - Medici, Valentina

AU - Virata, Maria C.

AU - Peerson, Janet M.

AU - Stabler, Sally P.

AU - French, Samuel W.

AU - Gregory, Jesse F.

AU - Albanese, Anthony

AU - Bowlus, Christopher

AU - Devaraj, Sridevi

AU - Panacek, Edward A

AU - Richards, John R

AU - Halsted, Charles H.

PY - 2011/11

Y1 - 2011/11

N2 - Background: S-adenosyl-L-methionine (SAM) is the methyl donor for all methylation reactions and regulates the synthesis of glutathione, the main cellular antioxidant. Previous experimental studies suggested that SAM may benefit patients with established alcoholic liver diseases (ALDs). The aim of this study was to determine the efficacy of SAM in treatment for ALD in a 24-week trial. The primary endpoints were changes in serum aminotransferase levels and liver histopathology scores, and the secondary endpoints were changes in serum levels of methionine metabolites. Methods: We randomized 37 patients with ALD to receive 1.2g of SAM by mouth or placebo daily. Subjects were required to remain abstinent from alcohol drinking. A baseline liver biopsy was performed in 24 subjects, and a posttreatment liver biopsy was performed in 14 subjects. Results: Fasting serum SAM levels were increased over timed intervals in the SAM treatment group. The entire cohort showed an overall improvement of AST, ALT, and bilirubin levels after 24weeks of treatment, but there were no differences between the treatment groups in any clinical or biochemical parameters nor any intra- or intergroup differences or changes in liver histopathology scores for steatosis, inflammation, fibrosis, and Mallory-Denk hyaline bodies. Conclusions: Whereas abstinence improved liver function, 24weeks of therapy with SAM was no more effective than placebo in the treatment for ALD.

AB - Background: S-adenosyl-L-methionine (SAM) is the methyl donor for all methylation reactions and regulates the synthesis of glutathione, the main cellular antioxidant. Previous experimental studies suggested that SAM may benefit patients with established alcoholic liver diseases (ALDs). The aim of this study was to determine the efficacy of SAM in treatment for ALD in a 24-week trial. The primary endpoints were changes in serum aminotransferase levels and liver histopathology scores, and the secondary endpoints were changes in serum levels of methionine metabolites. Methods: We randomized 37 patients with ALD to receive 1.2g of SAM by mouth or placebo daily. Subjects were required to remain abstinent from alcohol drinking. A baseline liver biopsy was performed in 24 subjects, and a posttreatment liver biopsy was performed in 14 subjects. Results: Fasting serum SAM levels were increased over timed intervals in the SAM treatment group. The entire cohort showed an overall improvement of AST, ALT, and bilirubin levels after 24weeks of treatment, but there were no differences between the treatment groups in any clinical or biochemical parameters nor any intra- or intergroup differences or changes in liver histopathology scores for steatosis, inflammation, fibrosis, and Mallory-Denk hyaline bodies. Conclusions: Whereas abstinence improved liver function, 24weeks of therapy with SAM was no more effective than placebo in the treatment for ALD.

KW - Alcoholic liver disease

KW - S-adenosyl-L-methionine

KW - S-adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=80055103499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055103499&partnerID=8YFLogxK

U2 - 10.1111/j.1530-0277.2011.01547.x

DO - 10.1111/j.1530-0277.2011.01547.x

M3 - Article

VL - 35

SP - 1960

EP - 1965

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 11

ER -